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INTRODUCTION 
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Carcinogenesis 
It is generally assumed that the neoplastic initiation leads to the appearance of a cell clone 
that, following an initial mutation, can prevail over the others because of its increased 
replicative activity and/or because of its being refractory to the pro-apoptotic stimuli. 
Furthermore, additional genetic alterations and selective mechanisms generate new different 
subclones, which are able to circumvent the tissue barriers and to invade the surrounding 
normal tissues. 
Recently, the cancer stem cell model for explaining tumorigenic processes has received 
increasing attention (Figure 1). This model postulates that tumours are driven and maintained 
by a smaller subpopulation of cells that have the capacity to self-renew and differentiate 
generating a cell progeny which make up the bulk of a tumour (Clarke MF et al.2006). The 
former population has been called cancer stem cells (CSCs), tumorigenic cancer cells, or 
tumour-initiating cells, by various investigators, to point out that these are able to form new 
tumours when transplanted into immune-deficient animals (Clarke MF et al.2006). 
 
 
The cancer stem cell might appear after mutations in specific stem cells or early stem cell progenitors. 
It is also possible that cancer stem cells can be derived from differentiated cells. There might be 
numerous factors in the host microenvironment that trigger the initial steps of tumour formation 
(Nature 2005). 
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Early evidence for the existence of CSCs came from studies of acute myelogenous leukemia 
(AML), while their presence has been recently demonstrated in many solid tumours, including 
glioblastoma, medulloblastoma, breast cancer, melanoma, prostate cancer (Takaishi S et al. 
2008) and thyroid (Zito G et al. 2008). The recognition of CSCs has profound implications for 
cancer biology and therapy since it is postulated that their eradication is a critical determinant 
in achieving appropriate therapeutic results. It has been proposed that CSCs may be 
particularly resistant to chemotherapy and radiation therapy as has been shown in a study with 
glioblastoma (Bao S et al. 2006). 
The carcinogenetic process may be accelerated by repeated exposures to carcinogenic stimuli 
or by selection pressures favouring the autonomous clonal derivatives. 
The tumor progression (Figure) is characterized by the expression of additional morphological 
and behavioural alterations leading the neoplastic cells to acquire a locally invasive 
phenotype. These cellular changes are most likely the result of a so-called epithelial-
mesenchymal transition (EMT) that is an orchestrated series of events in which cell-cell and 
cell-matrix interactions are damaged or destroyed. 
 
 
As a consequence, epithelial cells escape from the tissue border concurrently with the 
cytoskeleton reorganization which confers to the cells the ability to move through a three-
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dimensional ECM, while a new transcriptional program is induced to maintain the 
mesenchymal phenotype. 
Moreover, during progression, the detached epithelial cells acquire the ability to degrade the 
basal lamina and penetrate into the surrounding stroma, to form metastases. In particular, tight 
junctions, which typically maintain apico-basal polarity, dissolve allowing the mixing of 
apical and basolateral membrane proteins, adherens and gap junctions are disassembled and 
cell surface proteins such as E-cadherin and epithelial-specific integrins are replaced by N-
cadherin and integrins specific of the extracellular components. The actin cytoskeleton is 
remodelled into stress fibers which accumulate in the areas of cell protrusions. The epithelial 
intermediate filaments, cytokeratins, are replaced by vimentin. In the meanwhile, the 
underlying basement membrane is degraded and the cell invades and moves into the 
surrounding stroma, devoid of cell-cell contacts . 
In this new context, tumor cells alter the characteristics of the adjacent stroma to create a 
supportive microenvironment. This is strongly supported by evidence that over 80% of the 
fibroblasts demonstrate an activated phenotype in breast cancer for which they have been 
named cancer associated fibroblasts, CAFs, (Liotta LA et al. 2001). Likewise, previous work 
by our group demonstrated that fibroblasts, when co-cultured with the breast cancer cell line 
8701-BC, induce considerable proteomic modulations, mainly in the cytoskeleton proteins 
and glycolytic enzymes. Additionally, fibroblast-conditioned medium increased neoplastic 
cell proliferation and invasion; suggesting that fibroblast stimulation may enhance the 
malignant potential or breast cancer cells in vitro (Cancemi P et al. 2010). 
It has been shown that fibroblasts play a pivotal role in tumor invasion by secreting various 
matrix-degrading proteases as well as their activators such as uPA (Camps JL et al. 1990). 
uPA can cleave MMPs to activate these proteins, and up-regulation of MMPs activity results 
in significant ECM degradation, which contribute to angiogenesis and metastasis. The tissue 
inhibitors of metalloproteinases (TIMPs) have been shown to down-regulate MMPs activity. 
TIMPs can also regulate other growth factors indicating that TIMPs may also be involved in 
some important oncogenic signal pathways (Flavell SJ et al. 2008). 
Warburg Effect 
It is now emerging that the tumor microenvironment influences cell proliferation rate of and 
may have a strong effect on tumor progression and resistance to therapy (Hoogsteen IJ et al. 
2007).  
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In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative 
phosphorylation to generate the energy needed for cellular processes, most cancer cells 
instead rely on aerobic glycolysis, a phenomenon termed “Warburg effect”, because it has 
been described firstly by Otto Warburg. 
It is only under anaerobic conditions that differentiated cells produce large amounts of lactate. 
In contrast, most cancer cells produce large quantities of lactate according to the availability 
of oxygen and hence their metabolism is often referred to as “aerobic glycolysis”. Warburg 
originally hypothesized that cancer cells develop a defect in mitochondria that leads to 
impaired aerobic respiration and a subsequent reliance on glycolytic metabolism. However, 
subsequent work showed that mitochondrial function is not impaired in most cancer cells, 
suggesting an alternative explanation for aerobic glycolysis in cancer cells. 
One proposed explanation for Warburg‟s observation is that tumor hypoxia selects for cells 
dependent on anaerobic metabolism (Gatenby RA et al. 2004). Tumors are characterized by 
gradients of O2 levels, based on the distance of tumor cells from a functional blood vessel. 
Tumor cells surrounding the blood vessel are well oxygenated, whereas the tumor cells more 
distant from the vessel are poorly oxygenated and express high levels of HIF-1 (Hypoxia-
Inducible Factors). Several evidences suggested the existence of a “metabolic symbiosis” 
between hypoxic and aerobic cancer cells, in which lactate produced by hypoxic cells is taken 
up by aerobic cells, which use it as their principal substrate for oxidative phosphorylation.  
Although the altered metabolism in cancer has been well documented, the exact mechanisms 
leading to increased glycolysis and abnormal tumor cell growth under hypoxic conditions are 
not completely understood. A possible link could be the activity of the "early response" gene 
c-myc, because of its frequent overexpression in transformed cells, its stimulatory effect on 
cell growth (Hurlin PJ et al. 2004), and its ability to upregulate the transcription of several 
glycolytic enzymes (Osthus RC et al. 2000) Myc is overexpressed in approximately 70% of 
all human tumors (Gordan JD et al. 2007), and activate α-enolase (48 KDa), a glycolytic 
enzyme which catalyzes the conversion of 2-phosphoenolpyruvate from 2-phosphoglycerate 
(Kim JW et al. 2005). Indeed, α-enolase could act as a hypoxic stress protein which may 
contribute to low oxygen tolerance of tumors by increasing anaerobic metabolism (Pancholi V 
2001)  
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Hypoxia and Angiogenesis 
As a result of variable blood flow (oxygen supply) and rapid utilization of glucose within 
solid tumors (oxygen utilization), most tumor cells are exposed to a microenvironment that 
may be hypoxic. Hypoxia is quite common in breast cancer where it has been related to poor 
prognosis (Vleugel MM et al. 2005) with increased risk for tumor recurrence and metastasis. 
The hypoxic response is significantly controlled in most cells by HIF-1, a heterodimeric 
transcription factor composed of the nearly ubiquitous HIF-1α and its dimerization partner 
HIF-1β. HIF-1 activates approximately 200 genes encoding proteins that regulate cellular 
metabolism, proliferation, motility, haematopoiesis, and angiogenesis (Semenza GL 2000). 
Upon initiation of the hypoxic signal, HIF1-α translocates to the nucleus, dimerizes with 
HIF1-β to form the HIF-1 complex and induces the expression of its transcriptional targets via 
binding to hypoxia-responsive elements (HREs) (Chilov D et al. 1999).  
In response to various alterations in the microenvironment, and in particular, to intratumoral 
hypoxia, angiogenesis-stimulating factors produced by the cells themselves induce the 
formation of new blood vessels from pre-existing vasculature, to increase delivery of oxygen 
and nutrients to tissues. Many angiogenic genes, such as VEGF, angiopoietin-2, VEGF 
receptors (Flt1 and KDR), and neuropilin-1 (Hickey MM et al. 2006 and Simons M 2005) are 
induced by hypoxia through several mechanisms, including direct transcriptional activation by 
HIFs or indirect up-regulation by HIF-induced molecules. In addition, other transcription 
factors induced by hypoxia, such as Related Transcription Enhancer Factor-1 (RTEF-1) and 
Early Growth Response 1 (EGR-1), can target VEGF to enhance angiogenesis (Shie JL et al. 
2004 and Yan SF et al. 2000). Additional angiogenic growth factors such as IGF are also 
induced by hypoxia, but can signal through a HIF-1-independent pathway (Slomiany MG et 
al. 2006). 
However, unlike normal tissues, the newly formed vascular network has a number of 
"defects", both structurally and functionally (expansion, basement membranes and endothelial 
surfaces incomplete or absent, irregular and tortuous architecture, arterial-venous shunts, 
blind ends and lack of contractile components of the wall) (Vaupel P et al. 1989), resulting in 
an irregular blood flow that sometimes reduce the transport of oxygen and nutrients to cancer 
cells.  
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Thyroid Cancer 
The thyroid is a endocrine gland that controls heart rate, blood pressure, temperature and 
metabolism by producing of thyroid hormones, known as triiodothyronine (T3) and thyroxine 
(T4). The follicle represents the structural and functional unit of the thyroid gland and consists 
of two cell populations: Follicular cells (principal cells) which represent the thyroid 
parenchymal component and produce T3 and T4 and Parafollicular cells (C cells) located in 
the periphery of the follicles produce and secrete calcitonin hormone that plays a role in 
calcium homeostasis (Figure).  
 
Thyroid cancer is the most common malignancy of the endocrine system and the incidence is 
increasing than to others types cancer. This fact could be due to the enhancement of 
diagnostic tecniques (thyroid ultrasound, neck imaging and fine-needle aspiration biopsy) and 
for the same reason it is recorded also an significantly increasing of survival rates for thyroid 
cancer.  
Thyroid cancer can occur in any age group, with an incidence 3 times higher in women than 
in men (Hölzer S and Dudeck J 2000), its aggressiveness increasing significantly in older 
patients. 
The etiology of most thyroid carcinomas is not well understood, but as in every type of 
cancer, they depend from combination of enviromental and genetic factors. Exposure to 
ionizing radiation, especially during childhood, remains the only enviromental factor clearly 
associated with benign and malignant thyroid tumors in humans (Schlumberger MJ 2000). 
Moreover epidemiologic, experimental and clinical evidences suggest that exposure to 
ionizing radiation may trigger a series of abnormalities that lead to genetic instability and thus 
cancer development (Ward LS et al.1998). It is been displayed also the involvement of 
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geographic, ethnic and dietary factors in the risk of sporadic thyroid cancer (Farid NR et 
al.1994, Schlumberger MJ 2000 and Kazakov VS et al.1992). 
The genetic abnormalities play a crucial role in thyroid tumorigenesis and have been 
extensively explored over the last two decades due to their importance as potential targets for 
novel therapeutic approaches.  
In spite of the progress in the treatment of thyroid malignant tumors by traditional methods 
(surgical and/or chemotherapy, radiotherapy), 10-20% of these patients die from advanced 
differentiated, poorly and undifferentiated thyroid tumors. Therefore, alternative therapies are 
of interest because of the possibility of developing selective targeting approaches, such as 
using of tissue-specific molecules directed against tumor cells. 
Hystopathological classification 
There are four histological types of thyroid cancer: papillary, follicular and anaplastic 
carcinomas (PTC, FTC and ATC respectively) which arise from follicular epithelium and 
medullary carcinoma (MTC) that arises from parafollicular epithelium. Moreover PTC, FTC 
and MTC are well-differentiated thyroid carcinomas, while ATC is characterized as 
undifferentiated. 
PTC is the most common form of thyroid cancer, accounting for about 75-80% of thyroid 
malignancies (Thyroid Carcinoma Task Force 2001) with a 1% death rate and an 
approximately 5% recurrence rate (Hay ID 1990). It represents the most common pediatric 
thyroid malignancy and most papillary thyroid carcinomas (PTCs) in adults occur between 20 
and 50 years of age (Davies L and Welch HG 2002). The PTC patient has the highest 20-year 
survival (99%) in the low-risk group, whereas survival is only 43% in the high-risk group; 
distant metastases are uncommon but if present, they are lymphatic and the prognosis is poor. 
FTC cases account for about 15% of all thyroid cancer cases. FTC is less common in younger 
adults and children than papillary cancer, while it is characterized by a 20-year survival of 
about 97% in the low-risk group and 49% in the high-risk group; it is more common among 
elderly patients. This type of thyroid cancer is more aggressive than PTC and tends to spread 
through the bloodstream to other parts of the body (vascular invasion is characteristic of 
follicular carcinoma), and therefore distant metastasis is more common (Shaha AR et al.1996 
and Shaha AR et al.1995). 
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ATC is the least common (accounting for 5%-15% of primary malignant thyroid neoplasms) 
and the most deadly type of thyroid cancer. It is characterized by sudden, rapidly growing 
thyroid mass, mostly arising from a benign thyroid disease or a pre-existing differentiated 
thyroid carcinoma. It tends to occur most often among elderly women and in iodine-deficient 
areas, or in a pre-existing goiter, while it is also rapidly fatal with a mean survival of 6 months 
after diagnosis (Giuffrida D and Gharib H 2000, Ain KB 1998). ATC is always refractory to 
conventional therapies including surgery, radioactive iodine and chemotherapy (Ain KB 
1999). 
MTC is a neuroendocrine malignancy that accounts for 3 to 10% of all thyroid cancer cases, 
but bears significant mortality (Kebebew E et al.2000). Among medullary thyroid carcinomas 
(MTCs), 25% are sporadic, whereas 75% are inherited as the predominant component of the 
multiple endocrine neoplasia type 2 (MEN2) syndromes (MEN2A, MEN2B and familial 
MTC) (Ball DW et al.2007). MTC is less common and more aggressive than PTC or FTC, 
and tumor tends to spread to lymph nodes very early and to distant sites via the blood stream 
with excessive calcitonin production (Ball DW et al.2007). This cancer is treated with 
difficulty and has a much lower cure rate than do the „well differentiated‟ thyroid carcinomas 
(PTC and FTC) (Shaha AR et al.1996 and Shaha AR et al.1995), but cure rates are higher 
than they are for ATC. The recorded overall 10-year survival is about 60-70% ((Ball DW et 
al.2007 and Moley JF et al.2003). 
 
Genetic Basis of Thyroid Cancer 
Numerous genetic abnormalities are been found in different histotypes of thyroid tumors 
including rearrangements, point mutations or other gene disruptions, each of which plays a 
role in disease pathogenesis. Most of these genetic alterations have been used as diagnostic 
tools and molecular targets. Genes implicated in thyroid tumorigenesis are described below. 
The RAS oncogenes were the first to be associated with thyroid cancer. Members of the RAS 
family are signal-transducing proteins that share properties with the G-proteins. Genetic 
alterations in the four isoforms of Ras proto-oncogene (H-RAS, K-RAS, N-RAS and B-RAS) 
have been described in many tumor types.  
Point mutations of RAS determine the encoding of an active protein form and the constitutive 
activation of MAP kinase pathway that send cell proliferation signals. The complex RAS-
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initiated MAPK-terminated cascade signaling is regarded as crucial for the development of 
thyroid cancer. Mutation of the phosphatidylinosibol-3-kinase catalytic alpha polypeptide 
(PIK3CA) gene (the product of which binds specifically with RAS and activates PI3K/Akt 
pathway) also has an important role in thyroid tumorigenesis (Wu G et al.2005 and Hou P et 
al.2007). 
RAS point mutations are uncommon in PTCs, with an overall frequency of less than 10% 
(Namba H et al.1990 and Capella G et al.1996). Moreover, these genetic alterations appear to 
confer a predisposition to the development of both poorly differentiated and undifferentiated 
carcinomas (Nikiforova MN et al.2003). 
 
The p53 gene encodes a nuclear transcription factor that plays a key role in cell cycle 
regulation, DNA repair, and apoptosis and acts a tumor suppressor gene. Alterations of the 
p53 gene are a peculiar feature in ATCs (Ito T et al.1992 and Donghi R et al.1993). Moreover, 
the accumulation of p53 protein, frequently caused by p53 mutations, characterizes tumoral 
areas with a less differentiated phenotype (Donghi R et al.1993 and Matias-Guiu X et 
al.1994). Conversely, p53 gene mutations are rare in PTCs or these genetic modifications 
represent a late mutational event (Salvatore D et al 1996). All the above strongly suggest that 
p53 inactivation is important in tumor progression e in development of a aggressive 
phenotype (Nikiforov YE 2004). 
 
The PTEN gene, which acts as a tumor suppressor gene, encodes a protein that is involved in 
the regulation of cell division and plays a role in intracellular signaling. It should be noted 
also that PTEN acts in opposition to phosphatidylinosibol-3-kinase (PIK3), therefore it is 
considered as a regulator for cell cycle, translation, and apoptosis (Simpson L and Parsons R 
2001). Mutations of this gene contribute to the development of a multitude of cancer types 
(Gimm O et al.2000). 
In particular, Gimm et al. (Gimm O et al.2000), showed a 20-30% frequency of hemizygous 
deletions of the PTEN gene in PTCs and the loss of PTEN function is associated to an 
advanced stage of this cancer histotype (Garcia-Rostan et al.2006, Fagin JA and Mitsiades N 
2008). Moreover, 60% of undifferentiated carcinomas show hemizygous PTEN deletions 
(Gimm O et al.2000). 
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The RET gene plays a critical role in cell differentiation, proliferation and cell survival of 
nerve cells. The gene  encodes a tyrosine kinase receptor that is activated by interacting with a 
multicomponent complex that includes a soluble ligand family, the glial cell line-derived 
neurotrotrophic factors (GDNF), and also a family of cell surface bound coreceptors (LiVolsi 
VA et al.2004). This binding determinates the receptor dimerization leading to protein 
autophosphorylation on tyrosine residues and initiation of the proliferation signaling cascade. 
Subsequent studies have demonstrated a novel form of RET (RET/PTC) resulting from 
different gene rearrangements which are been identified in PTC. The most common 
rearranged forms of this gene are RET/PTC1, RET/PTC2 and RET/PTC3. Moreover, 
RET/PTC rearrangement leads to the costitutive activation of the MAPK pathway and thus, 
these genetic alterations are being actively explored as therapeutic targets for thyroid cancer. 
In recent studies, RET rearrangements have emerged as the second most common genetic 
abnormality found in PTCs and these genetic alterations are particularly common in tumors in 
pediatric patients (50-60%) and in patients exposed to accidental/therapeutic radiation during 
childhood (60-70%) (DeLellis RA 2006). Therefore, ionizing radiation considered as the 
major risk factor for development of PTC, can directly induce RET recombination events. 
Finally, several studies have emphasized the fact that rearrangements of this gene are 
associated with PTCs lacking evidence of progression to poorly differentiated or anaplastic 
carcinomas (Tallini G and Asa SL 2001 and Quiros RM et al.2005). 
 
The PAX8-PPARγ gene fusion has been identified in FTC cases in association with the 
presence of a recurrent translocation [t(2;3) (q13;p25)] (Kroll TG et al.2000). The 
consequence of this translocation is the fusion of the DNA binding domains of the thyroid 
transcription factor PAX8 to domains A-F of the PPARγ1 (Kroll TG et al.2000 and 
Nikiforova MN et al.2002). In a comparative study of RAS mutations and PPARγ 
rearrangements, 49% of conventional FTC had RAS mutations, 35% had PAX8-PPARγ 
rearrangements, only 3% had both abnormalities (Nikiforova MN et al.2003), while 12% were 
negative for both. The results highlight the crucial role of these genetic alterations in FTC 
progression. 
 
The NTRK1 gene is located on chromosome 1q22 and encodes the receptor for the nerve 
growth factor (NGF). Similar to RET, NTRK1 undergoes oncogenic activation by 
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chromosomal rearrangement (Greco A et al.2004), but these mutational events are less 
frequently found in PTCs than RET rearrangements (Bongarzone I et al.1998). Moreover, the 
prevalence of NTRK1 rearrangements is approximately 3% in post-Chernobyl PTCs (Rabes 
HM et al.2000). 
 
The β-catenin protein encoded by the CTNNB1 gene (chromosome 3p22- 21.3) has a role in 
cell adhesion via its interaction with the cytoplasmic tail of cadherins and in the Wnt signaling 
pathway involving a complex network of proteins that play a crucial role in carcinogenesis 
(Garcia-Rostan G et al.2001). 
Garcia-Rostan et al. (Garcia-Rostan G et al.2001), have demonstrated that CTNNB1 
mutations and nuclear (rather than plasma membrane) localization of β-catenin are restricted 
to poorly differentiated or undifferentiated carcinomas. These findings highlight the important 
role of CTNNB1 mutations in the progression of thyroid cancer. 
 
The Sodium Iodine Symporter (NIS) is a membrane glycoprotein that mediates active iodide 
uptake in the thyroid gland and several extrathyroidal tissues. In thyroid tumours it is been 
observed a loss/reduced function of NIS and thus the reduced iodide uptake capacity that 
gives to tumor cells a proliferative advantage. In anaplastic thyroid carcinomas (ATCs) this 
altered capacity is mainly due to defects occurring mainly at gene expression level of NIS, but 
in some case involving post-transcriptional or other unknown alterations (Filetti S et al.1999 
and Dohan O et al.2003). 
Moreover, the lost ability to concentrate the radioiodine is used as very effective tool for 
diagnosis and treatment for both tumour remnants or distant metastases (Schlumberger M et 
al.1986). 
 
The BRAF gene (V-raf murine sarcoma viral oncogene homolog B1) encodes a 
serine/threonine protein kinase and it plays critical roles in cell proliferation, differentiation 
and apoptosis by MAPK signaling pathway. The RAF family includes three isoforms: ARAF, 
BRAF, and CRAF. In particular, CRAF is expressed ubiquitously, whereas BRAF is 
expressed at higher levels in hemopoietic cells, neurons, and testes (Daum G et al.1994). 
BRAF is also the predominant isoform in thyroid follicular cells and is more efficient 
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activator of the MAPK pathway by phosphorylating MEKs (Peyssonnaux C and Eychene A 
2001). 
In PTC, BRAF mutations have been identified in approximately 40-70% of the tumours 
(Ciampi R and Nikiforov YE 2005 and Trovisco V et al.2006), and can occur early 
(Nikiforova MN et al.2003). The most common BRAF mutation is the T1799A transversion 
mutation (formerly known as BRAF T1796A mutation) in exon 15 of the gene. This mutation 
causes a V600E (formerly known as V599E) amino acid substitution in the protein and 
confers the kinase oncogenic function through constitutive activation of the MAPK signaling 
pathway (Davies H et al.2002). The BRAF V600E mutation is the most common genetic 
change in PTC (Xing M 2005). In contrast, this genetic alteration is not found in any other 
form of well-differentiated follicular neoplasm or MTC (Xing M 2005). Practically, in PTCs 
there seems to be no overlap between RET/PTC, BRAF or RAS mutations, which altogether 
were found to be present in 66% of cases (Kimura ET et al.2003). Moreover, Pizzolanti G. et 
al. (Pizzolanti G et al.2007) have demonstrated that BRAF V600E mutation detected on fine-
needle aspiration (FNA) specimens, more than RET/PTC rearrangerangements, is highly 
specific for PTC and its routine research might well be an adjunctive and integrative 
diagnostic tool for the preoperative diagnostic iter. 
In addition a substantial body of data indicates that the BRAF mutational status is a 
significant predictor of poor clinical outcome and it has been shown that this genetic 
alteration is associated to extra-thyroidal invasion (Xing M et al.2005). BRAF V600E is also 
often found in ATC (Begum S et al.2004), suggesting that this mutation may be involved in 
thyroid cancer progression to poorly differentiated and aggressive phenotypes (Nikiforova et 
al. 2003, Nikiforov YE 2004 and Quiros RM et al. 2005). All the above strongly suggest that 
BRAF V600E may be used as tool for diagnosis and prognosis of thyroid cancer.  
Finally, “in vitro” studies performed on thyroid cells suggest that BRAF V600E mutation 
promotes the invasion, by increasing the expression of certain metalloproteinases (MMP-3, 
MMP-9, MMP-13) (Puxeddu E and Moretti S 2007) and it reduces expression and 
localization on the plasmatic membrane of NIS (Riesco-Eizaguirre G et al.2006).  
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Two Hypotheses for ATC development 
In order to explain the cascade of events that lead to ATC development two hypotheses are 
been developed, taking into consideration all the factors involved and their interaction with 
genetic susceptibility. 
According to the first hypothesis, it is believed that ATC is derived from the follicular 
epithelial cells and it represents a terminal dedifferentiation of preexisting differentiated 
carcinoma. In dedifferentiation process oncogenes or tumor suppressor genes which foster the 
development of malignant phenotypes are altered. 
Molecular genetic studies suggest that RAS oncogenes are frequently mutated in ATC as a 
result of progression from RAS-mutated FTCs (Lemoine NR 1989 and Suarez HG 1998). In 
contrast, RET/PTC rearrangements have not been detected in ATC (Tallini G et al.1998) and 
thus it is believed that this tumor histotype may derive from other oncogene-mutated PTC. 
Moreover, p53 frequently mutated in ATC may play a critical role in promoting 
dedifferentiation of PTC or FTC. BRAF V600E mutation that is peculiar for PTC is often 
found in ATC (Begum S et al.2004), suggesting that also this mutation may be involved in 
differentiation process (Nikiforova et al.2003, Nikiforov YE 2004 and Quiros RM et al.2005). 
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Finally, careful histopathologic examination of ATCs reveals that many of them contain a 
papillary structure or follicular components in focal areas. 
The second hypothesis suggests that ATC may derive from thyroid fetal cells. A considerable 
number of researches has demonstrated that cancer cells derive from immature progenitor or 
stem cells, but not from well-differentiated cells (Takano T and Amino N 2000, Takano T 
2004). Takano (Takano T 2004) has explained well the clinical and biological features of this 
hypothesis and there are the molecular evidences that support his theory for thyroid 
carcinoma. This hypothesis suggests that thyroid cancer cells are generated from fetal cells by 
proliferation without differentiation and that oncogenes play a crucial role in preventing the 
differentiation of fetal cells. Therefore, any defect or inhibition of differentiation may lead to 
cancer cell formation. ATC, PTC and FTC derive from thyroid stem cells, thyroblasts and 
prothyrocytes, respectively.  
In conclusion, different clinical and molecular evidences support one or the other hypothesis, 
but the mechanism of thyroid cancer development is unclear. Therefore, it remains 
controversial as to whether ATC is derive from a terminal dedifferentiation of preexisting 
carcinoma or it arises from thyroid fetal cells. 
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Thyroid Biomarkers 
Every cell type has a unique molecular signature, referred to as biomarkers, which are 
identifiable characteristics such as levels or activities of genes, proteins or other molecular 
features. 
Tumor biomarkers are molecules often produced by the tumor itself or the host system in 
response to the tumor and provide the biological material to determine the risk of getting 
cancer, to detect cancer, to classify cancer, or to provide insight into prognosis and therefore a 
therapeutic advantage. Tumor biomarkers include cancer-specific mutations or changes in 
gene expression or promoter methylation, which can result in alterations in protein expression 
(Tainsky MA 2009). Therefore, the biomarkers are subject to dynamic modulation, and are 
expected to enhance our understanding of pathological processes but also drug metabolism. 
Herberman (Herberman, RB et al.1977) proposed five criteria for a biomarker to be useful in 
cancer detection: 1- measurement should be simple, reproducible, easily available and cost 
effective; 2- should detect a quantitative difference so that it can distinguish those with or 
without disease; 3- should have high sensitivity; 4- should be able to monitor for recurrence 
of disease, and 5- should have high specificity. 
It has been over 40 years since biological markers were first introduced as a way to detect and 
manage thyroid cancer (Milhaud G et al.1974 and Melvin KE et al.1971). Thyroglobulin and 
calcitonin represent two of the earliest biomarkers discovered in thyroid cancer (Van Herle AJ 
et al.1973 and Tashijan AH et al.1970) and their discovery has helped revolutionize the 
management of patients with thyroid cancer in terms of earlier diagnosis and more sensitive 
follow-up. Biomarker studies have expanded to include genetic mutations and molecular 
changes to detect some of the earliest events in thyroid tumorigenesis. In conclusion, genomic 
and proteomic assays have become the latest methods for identifying a multitude of 
biomarkers which reflect a molecular profile associated to specific tumor type. 
 
Serum-Based Biomarkers 
Serum biomarkers represent the first generation of thyroid biomarkers. Ideally, a serum 
biomarker is one that is highly sensitive and specific, can establish diagnostic certainty and 
can be easily measured (Jensen MB et al.2008). Serum biomarkers for thyroid cancer 
detection are: 
Calcitonin an anti-hypercalcemic hormone is secreted by the parafollicular cells and it is used 
as a serum-based marker for MTC (Holyoke ED et al.1981). The calcitonin detection and 
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FNA citology in fact has helped optimize the sensitivity and specificity of MTC diagnosing . 
However, it is not a foolproof test and calcitonin measurements differs depending on the 
assays used (Bieglmayer C et al.2007). Radioimmunoassays were initially used to detect 
calcitonin in the circulation. These assays are results less specific because they used 
polyclonal antibodies which detected several different monomers of this protein (Guilloteau D 
et al.1990). However, studies have demonstrated that immunoradiometric assays and 
immunochemiluminescent assays, which are based on monoclonal antibodies, can eliminate 
variation and improve reliability and sensitivity in the measurement of calcitonin 
(d'Herbomez M et al.2007 and Toledo SP et al.2009). In addition, the increased calcitonin 
levels are not exclusive to MTC but there are other conditions when the level of calcitonin is 
altered, such as C-cell hyperplasia, thyroid nodules of follicular cell origin, increasing age, 
increased body-mass index, cigarette smoking, breast feeding and small cell carcinoma of the 
lung (d'Herbomez M et al.2007 and van Veelen W et al.2009). 
 
Thyroglobulin is a glycoprotein that is synthesized by thyroid follicular cells and is the 
precursor molecule for the production of T3 and T4 hormones (Wong J et al.2008). This 
protein is a valuable serum marker for detecting recurrent or persistent well-differentiated 
thyroid cancer of follicular cell origin (Whitley RJ and Ain KB 2004, Gupta M and Chia SY 
2007). Although mainly localized in the colloid, thyroglobulin can be resorbed into the 
peripheral circulation and thus this protein can be detected in serum. However, there are some 
conditions that make it difficult to interpret the assays results. For example, the presence of 
anti-thyroglobulin antibodies can interfere with blood thyroglobulin levels (Spencer CA et 
al.2005 and Haugen BR et al.1999) and assays are not as reliable when patients are on thyroid 
hormone suppressive therapy. In addition, there are many benign thyroid conditions (e.g., 
thyroiditis, thyrotoxicosis, benign adenoma and iodine deficiency) which may cause false-
positive results (Refetoff S and Lever EG 1983). 
 
In conclusion, calcitonin and thyroglobulin biomarkers have helped improve the management 
of patients with thyroid cancer, but further advances are necessary because the assays have 
several limitations. Recent molecular studies have used reverse transcriptase polymerase 
chain reaction (RT-PCR) to measure mRNA levels in the circulation. 
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Mutation Based Biomarkers 
The next step in the evolution of thyroid cancer biomarkers was the study of genetic 
mutations in thyroid tumors. The most common molecular alterations in thyroid cancer 
include BRAF and RAS point mutations and RET/PTC and PAX8/PPARγ rearrangements. 
These nonoverlapping genetic alterations described previously are found in more than 70% of 
PTC and ATC and can be detected in surgically resected samples and FNA samples from 
thyroid nodules. The detection of these molecular markers may to improve significantly the 
accuracy of cancer diagnosis and allow more specific surgical and postsurgical management 
of patients with thyroid cancer. 
Moreover, the discovery of single genetic mutations is important for understanding cancer 
formation, but single mutations are not practical clinical biomarkers for thyroid cancer. 
Therefore, DNA mutations panels are being explored as thyroid cancer biomarkers. This shift 
in approach happened because cancer development is a complex event that involves multiple 
genetic and possibly epigenetic events. 
 
Epigenetic Biomarkers 
Epigenetics is defined as the study of heritable changes in gene expression which are 
independent from DNA sequence modifications. Moreover, one of the most exciting aspects 
of epigenetic regulation is that unlike genetic mutations, these processes are easily reversible 
with various therapeutic agents. Epigenetic mechanisms include DNA methylation, histone 
protein modification, nucleosome positioning, and microRNA silencing. In thyroid cancer 
DNA methylation, histone modifications and microRNA silencing have all been studied, but 
there is minimal data on nucleosome positioning. 
In particular, hypermethylation of multiple genes has been identified in association with the 
PIK3/AKT pathway in FTC and with the MAPK pathway in PTC (Alvarez-Nuñez F et 
al.2006 and Hoque MO et al.2005). Moreover, most studies have demonstrated a miRNAs 
upregulation in PTC and FTC (Nikiforova MN et al.2009) A few trials using FNA samples 
have established miRNA as a possible diagnostic tool, but larger clinical trials are needed to 
confirm the utility of miRNAs as a clinical biomarker (Chen YT et al.2008). 
 
Genomics and Proteomics 
The terms “genomics and proteomics” refer to the analysis of gene sequence and protein 
production, respectively. Advances performed in these fields have contributed to the 
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understanding of signal transduction pathways that control important cellular processes, such 
as growth, differentiation and death of cells. Since defects in these processes may result in the 
pathological phenotypes expression, it becomes crucial the identification of candidate disease 
genes, the proteins study which are responsible of genetic function expression and 
consequently the detection of genetic or protein changes. This integrated approach, called 
"systems biology", aims to recognize early onset of disease, institute preventive treatment and 
identify new molecular targets for cancer therapy.  
Moreover, “genomics and proteomics” are characterized from application of throughput or 
large- scale experimental methodologies combined with statistical and computational 
analysis. The fundamental strategy is to expand the biological investigation from study of 
single genes or proteins to analysis of genetic and proteomic profiles in a systematic fashion. 
In conclusion, the hope is that the study of gene and protein expression profiling will lead 
someday to personalized medicine that allows to develop specific therapeutic strategies 
tailored of patient needs. 
Genomics 
The genomics field was focused initially on mapping the human genome and understanding 
the effects of single genes in a system. Subsequently, the attention has shifted to identification 
of disease genetic signatures. Many different gene expression profiling technologies are 
currently in use, including cDNA microarrays, oligonucleotide arrays and Serial Analysis of 
Gene Expression (SAGE) (Mandruzzato S 2007 and Hoheisel JD 2006). 
In particular, DNA microarray analysis has allowed to define distinct expression profiles for 
the BRAF, RET/PTC and RAS mutation groups in PTCs (Giordano TJ et al.2005). Therefore, 
the data of this study suggest that approach may be useful for predict  tumors with these 
mutations. Other gene expression profile studies have identified distinct genetic signatures 
which correlate with the PAX8/PPARγ translocation in FTC (Lui WO et al.2005) and with 
RET/PTC rearrangements in radiation-induced PTC. The correlation with RET/PTC 
rearrangements may help to evaluate the invasion risk in PTC (Detours V et al.2007). 
However, contradictory findings are present in several studies; in fact genes which are 
involved in thyroid cancer and identified in individual studies are not consistently found 
across multiple studies. These experimental evidences suggest that the gene expression profile 
methodologies should be standardized to use these genetic signatures as biomarkers of thyroid 
cancer. 
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Proteomics 
Proteomic application to cancer is a common effort by several laboratories in the world to 
integrate knowledge on structure, function and dynamics of proteins involved in 
cancerogenesis (Pucci-Minafra I et al.2006). Numerous progress has been made in the past 
few years in generating large-scale data sets for protein-protein interactions, organelle 
composition, protein activity patterns and protein profiles associated to cancer. 
Before highthroughput proteomics was developed, the study of thyroid biomarkers is based 
on immunohistochemistry that combined with  FNA cytopathology has improved the 
diagnostic accuracy in indeterminate thyroid nodule FNA samples. 
 
Two immunohistochemical markers of thyroid cancer which have been extensively studied 
are galectin-3 and Hector Battifora mesothelial cell antibody (HMBE-1). 
Galectin-3, a lectin-binding protein, has multiple functions, including cell–cell and cell–
matrix adhesion, cell growth, neoplastic transformation and spread, cell cycle regulation and 
apoptosis, and cell repair processes. Galectin-3 has been found to be increased in several 
human malignant tumors, including well-differentiated follicular-derived thyroid carcinomas 
(Saggiorato E et al.2001). 
HBME-1 was originally described as a marker of mesothelial cells and it recognizes an 
unknown antigen expressed by those cells. It was later shown to also stain most PTCs, and 
also a fraction of FTCs, while adenomas are generally negative (Casey MB et al.2003 and 
Cheung CC et al.2001). 
However, the results for these markers were variables when each of these was examined 
individually. Some studies have demonstrated that these markers could differentiate between 
benign and malignant thyroid lesions and that the protein expression is varied depending on 
the PTC stage (Volante M et al.2004 and Rossi ED et al.2006), but they did not help for 
distinguish the histological variants of PTC. 
Several studies have demonstrated that the combined detection of galectin-3, HBME- together 
with cytokeratin-19 determines an sensitivity and specificity increasing of cancer diagnosis on 
tissue or FNA samples (Rossi ED et al.2006 and Wiseman SM et al.2008). Consequently, 
these results suggest that panels or patterns of these and other markers may represent the 
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future of analyzing protein expression to improve the diagnosis of the indeterminate thyroid 
nodular lesion. 
 
The study of thyroid biomarkers has now expanded to include the proteome analysis that 
investigates protein expression and modification, along with changes in protein activity and 
localization (Srinivas PR et al.2001). The information gained from the proteome reflects not 
only the genomic profile expressed from the cell, but also takes into account post-translational 
changes which are not detected at the mRNA level, as well as protein expression at different 
time points of neoplastic transformation (Srinivas PR et al.2001, Wilkins MR et al.1996 and 
Krause K et al.2009). Proteomic expression profiling high-throughput technologies include 
two-dimensional electrophoresis (2D-IPG), mass spectrometry analysis and ProteinChip 
technology (Wang JX et al.2006 and Wulfkuhle JD et al.2003). 
In particolar, Giusti et al. (Giusti et al.2007 and Giusti et al.2008) was the first group to 
analyze the fluid obtained from FNA of thyroid cancer by applying of proteomic 
methodologies. They performed a comparative proteome analysis to examine the global 
changes of FNA protein patterns of two variants of malignant PTC with the controls. Changes 
in protein expression were identified using two-dimensional electrophoresis (2D-IPG) and 
peptide mass fingerprinting via MALDI-TOF mass spectrometry (MS), as well as Western 
blot analysis. They discovered 17 protein spots that could reliably distinguish between 
papillary thyroid cancer and normal thyroid tissue. These proteins included for example 
transthyretin precursor (TTR), ferritin light chain (FLC), proteasome activator complex 
subunit 1 and 2 (PSME1 and 2), glyceraldehyde-3-phosphate dehydrogenase (G3P), lactate 
dehydrogenase chain B (LDHB), annexin A1(ANXA1) and cofilin-1 (COF1) (Giusti et 
al.2008). 
Moreover, a study has reported the presence of RET oncogene mutations in human MTC cell 
lines and thus it  has compared expression profiles of downstream signaling elements by using 
proteomic analysis and immunological validation (Gorla L et al.2009). These results have 
demonstrated that 41 phosphotyrosine proteins were detected downstream following RET 
activation and the EGFR pathway was over-expressed. 
 
In conclusion, although there are been numerous advances in thyroid biomarker research, an 
improvement of diagnostic tests and tumor aggressiveness predictors is necessary. Many 
thyroid cancer biomarkers have been identified, but few have made it into routine clinical 
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practice. Therefore, it is necessary the combined attendance of genomics and proteomics to 
find  reliable and clinically helpful biomarkers. New fields of research, such as  metabolomics 
or kinome, should be explored in thyroid cancer in order to implement the information 
known. 
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AIM OF THIS STUDY 
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Thyroid carcinomas are the 1-2% of all malignant tumors and, after those of the gonads, are 
the most common tumors of the endocrine system. 
Moreover, it consists of several histotypes with different molecular profiles, biological 
behaviour and risk profiles as described previously. In particular, our interest is been focused 
on PTC and ATC because these thyroid hystotypes are characterized by opposite phenotypic 
features . In fact, PTC represent approximately 80% of all thyroid malignancies and are 
characterized by a good prognosis. Differently, ATC which account for less than 5% of all 
thyroid cancers, is the most malignant thyroid neoplasm and is almost invariably fatal. 
Current clinical parameters with prognostic and predictive factors constitute important tools 
for the identification of thyroid cancer therapy and providing an efficient treatment, but an 
improvement of diagnostic tests and tumor aggressiveness predictors is necessary. 
To contribute to the knowledge of thyroid tumorigenesis, we performed a differential analysis 
of two thyroid cancer cell lines, derived respectively from papillary (B-CPAP) and anaplastic 
(8505C) thyroid carcinomas. These cell lines represent important model for the study of in 
vitro differentiated and undifferentiated tumors. 
The comparative analysis of the two cell lines has been structured on research different levels 
of and required the use of several experimental methodologies of cellular biology and 
proteomic analysis. Therefore, to characterize the phenotypes of B-CPAP and 8505C cell 
lines, the present study aims to: 
 
 Analyze the morphological characteristics by optical and scanning electron 
microscopy; 
 Evaluate the proliferative capabilities by application of MTS assays; 
 Create the reference maps for each cell line and confirm the protein identities of the  
through MALDI-TOF and/or N terminal sequencing;  
 Perform a comparative proteomic analysis between the  B-CPAP and 8505C cell lines 
and  thus find potential thyroid biomarkers and new functional pathways involved in 
thyroid cancer progression; 
 Assess the invasive capabilities through detection of gelatinase activity; 
 Evaluate the cell motility  by Scrach Assay. 
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In conclusion, we suggest that this approach may be useful for increasing the knowledge and 
the typisation of these thyroid tumors. Moreover, the proteomic analysis  may be useful for 
studying the mechanisms underlying the process of dedifferentiation and for identifying 
potential molecular markers associated with the PTC and ATC. 
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MATERIALS AND METHODS 
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Cell culture 
Human papillary thyroid carcinoma cell line, B-CPAP, and human anaplastic thyroid 
carcinoma cell line, 8505C, were kindly provided by the Laboratory of Endocrinology 
(University of Palermo, Italy). The cells were cultured in RPMI 1640, supplemented with 
10% foetal calf serum (FCS; GIBCO), L-glutamine 2 mM and antibiotics (100 units/ml 
penicillin and 100 ìg streptomycin) in a humidified incubator with 5% CO2 in air at 37°C. 
 
 
 
Cell proliferation assay 
Cell proliferation was determined by the use of a colorimetric tetrazolium compound 
(CellTiter 96, Promega). Briefly, 20 μL of CellTiter 96 was added to 100 μL of medium into 
each well containing the cells. After 1 h of incubation in a humidified, 5% CO2 atmosphere, 
the absorbance at 492 nm was read using a 96-well plate reader (Amersham). 
 
 
 
Protein extraction from cell culture and conditioned media preparation.  
Cell-lysates: After washing with ice-cold phosphate buffered saline (PBS), cells were 
carefully scraped and incubated on ice for 30 min with RIPA buffer (50 mM Tris pH 7.5, 
0.1% Nonidet P-40, 0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA) and a mixture of 
protease inhibitors (0.01% aprotinin, 10 mM sodium pyrophosphate, 2 mM sodium 
orthovanadate, 1mM PMSF). The total cellular lysates were centrifuged at 14.000 rpm for 8 
min to clear cell debris. 
Conditioned media preparation: Conditioned media from confluent B-CPAP and 8505C cells 
were harvested after 24h culture in RPMI 1640 without serum, centrifuged to remove cell 
debris and sterile filtered.  
Both cellular lysates and conditioned media were dialysed against ultrapure distilled water, 
lyophilised and stored at -80°C until analysis. The total protein concentration was determined 
by the Bradford method using bovine serum albumin as a standard (16). 
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Two Dimensional Gel Electrophoresis 
The proteins extracted from B-CPAP and 8505C cell lines were solubilised in a buffer 
containing 4% CHAPS, 40 mM Tris, 65 mM DTE (1,4-dithioerythritol) and a trace amount of 
bromophenol blue in 8 M urea. Aliquots of 45 μg (analytical gels) or 1.5 mg (preparative 
gels) of total proteins were separately mixed with 350 μL of rehydration solution containing 8 
M urea, 2% CHAPS, 10 mM DTE and 0.5% carrier anpholytes (Resolyte 3.5-10), and applied 
for IEF using commercial sigmoidal IPG strips, 18 cm long with pH range 3.0-10. The second 
dimension was carried out on 9-16% linear gradient polyacrylamide gels (SDS-PAGE), and 
the separated proteins were visualized by ammoniacal silver staining. Stained gels were 
digitized using a computing densitometer and analyzed with Image Master software 
(Amersham Biosciences, Sweden). 
 
 
 
Protein identification 
N-Terminal microsequencing was performed by automated Edman degradation in a protein 
sequencer (Procise, 419 Applied Biosystems) (17). 
Mass spectrometric sequencing was performed by Voyager DE-PRO (Applied Biosystems) 
mass spectrometer as described (18). Briefly, proteins were digested using sequencing-grade 
trypsin (20 μg/vial). The tryptic peptide extracts were dried and redissolved in 10 μL of 0.1% 
trifluoroacetic acid (TFA). The matrix, R-cyano-4-hydroxycinnamic acid (HCCA), was 
purchased from Sigma-Aldrich. A saturated solution of HCCA (1 μL) at 2 mg/200 μL in 
CH3CN/H2O (50:50 (v/v)) containing 0.1% TFA was mixed with 1 μL of peptide solution on 
the MALDI plate and left to dry. MALDI-TOF mass spectra were recorded in the 500-5000 
Da mass range, using a minimum of 100 shots of laser per spectrum. Delayed extraction 
source and reflector equipment allowed sufficient resolution to consider MH+ of 
monoisotopic peptide masses. Internal calibration was done using trypsin autolysis fragments 
at m/z 842.5100, 1045.5642, and 2211.1046 Da. Peptide mass fingerprinting was compared to 
the theoretical masses from the Swiss-Prot or NCBI sequence databases using Mascot 
http://www.matrixscience.com/. Typical search parameters were as follows: (50 ppm of mass 
tolerance, carbamidomethylation of cysteine residues, one missed enzymatic cleavage for 
trypsin, a minimum of four peptide mass hits was required for a match, methionine residues 
could be considered in oxidized form. 
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Scratch assay 
The confluent mono-layers of B-CPAP and 8505C cells were scraped with a p200 pipet tip. 
After removing cell debris with PBS, growth medium was added. The assays were monitored 
at different times (6h - 24h). from “scratch”.  
 
 
 
Zymography 
Aliquots of conditioned media of B-CPAP and 8505C corresponding to 10 µg of cell proteins 
were separated in acrilamide gel containg 0.1% gelatin. After the electrophoresis run, gel was 
rinsed in 50 mM Tris-HCl (pH 7.5) with 2.5 % Triton X-100 for 1 h. and incubated at 37°C 
for 18 h in a buffer containing 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 10 mM CaCl2. to 
detect gelatinases activity. Finally, the gel was stained with a solution of 0.2% Coomassie 
Brilliant Blue G-250 in 40% methanol and 10% acetic acid  and destained with a solution of 
7% methanol and 5% acetic acid, without dye. Clear zones against the blue background 
indicated the presence of proteolytic activity.  
 
 
 
Western Blotting  
For immune detection the gel was electrotransferred onto nitrocellulose membrane (HyBond 
ECL, Amersham) and stained with Ponceau S (Sigma). The membranes were then probed 
with one of the following monoclonal antibodies: anti-MMP-9 and MMP-2 (Santa Cruz). 
Following incubation with anti-mouse peroxidase-linked antibody (Santa Cruz sc-2005), the 
reaction was revealed by the ECL detection system, using high performance films (Hyperfilm 
ECL, Amersham). 
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RESULTS AND DISCUSSION 
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Morphological Analysis 
 
B-CPAP cell line, isolated from a differentiated thyroid cancer, shows rounded morphology 
and absence of cytoplasmic extensions. In contrast, 8505C cell line is characterized by a quite 
irregular morphology with membrane perturbation and numerous cytoplasmic extensions 
generally associated with high invasive phenotype. Figure (A-B) shows representative optical 
micrographs of B-CPAP and 8505C cells. As it is possible to observe B-CPAP displays a 
regular-rounded morphology with a refractive cytoplasm. After substrate adhesion, B-CPAP 
cells acquire a follicle-like structures, which include a variable number of cells often 
delimiting the small central cavity corresponding to the “holes” described by Fabien et al. In 
contrast, 8505C cells acquire a very irregular morphology and organization after substrate 
adhesion. A common feature shown by these cells was their ability to connect with each 
others by very long cytoplasmic bridges or spikes. 
 
 
 
Figure . Representative optical micrographs (20x) of B-CPAP (A) and 8505C (B) cell lines at 72h from the 
seeding. 
 
 
Electronic microscopy of B-CPAP and 8505C cells (Figure  A-B) confirmed the different 
arrangements of the cells. B-CPAP cell line forms the follicle-like structures, previously 
described, and cell surface appears almost irregular. 8505C cell line shows a polygonal cell 
shape with numerous cytoplasmic extensions. The morphological features of these cell lines 
are indicative of different malignant potentiality, suggesting that the 8505C cells are a more 
aggressive phenotype respect to the B-CPAP cells. 
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Figure . Representative electron micrographs (500x) of B-CPAP (A) and 8505C (B) cell lines at 72h from the 
seeding. 
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Cell Proliferation Assay 
 
Cell proliferation ability was determined at 24h, 48h, 96h, 5, 6, 7 and 9 days from seeding, 
using the MTS colorimetric assay, which measures dehydrogenase activity found in 
metabolically active cells. The experiment was performed as described in materials and 
methods. 
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Figure Cell growth of B-CPAP and 8505C cell lines by  MTS colorimetric assay. 
 
 
The figure  shows the growth curves of B-CPAP and 8505C cells where each point represents 
the mean of three replicates from three independent experiments (± SD). The results of the 
MTS assay show that in 8505C cells proliferation capacity is higher than in the B-CPAP cells. 
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Proteomic Analysis 
 
The study performed in our laboratory on lysates of B-CPAP and 8505C cells demonstrated 
qualitative and quantitative differences in the proteomic profiles between papillary and 
anaplastic cell lines. Anaplastic proteome showed a greater abundance of cellular proteins 
when compared with papillary proteome.  
 
Qualitative  profiling of B-CPAP and 8505C cell lines 
 
Figures show reference maps of B-CPAP (Fig.) and 8505C cell lines (Fig.), that have been 
analysed with Image Master 2D Platinum. The protein identities are marked with labels 
corresponding to the abbreviated name of Swiss-Prot database. 233 and 230 protein spots 
(including isoforms and variants) of B-CPAP and 8505C cells respectively, were identified in 
the maps. The protein identities were assessed by MALDI-TOF and/or N terminal 
sequencing.  
The identified proteins were clusterized according to our previous criteria, confirmed by the 
DAVID Bioinformatics database. Database has been utilized to provide functional 
interpretation of large lists of genes derived from genomic and proteomic studies. The 
program recognizes gene lists and displays results in terms of significance, by correlating to 
each group of genes two values that are Fisher exact P-value index and Benjamini FDR: False 
Discovery Rate. The first is a variant of the p-value that indicates whether the association of a 
gene in a given cluster is reliable or due to chance; the second parameter of significance is 
Benjamini, that correct the enrichment P-value to control false discovery rate. 
The gene list corresponding to the proteins was uploaded into DAVID Bioinformatics 
database that identified, with a certain degree of significance, the molecular pathways in 
which these proteins are involved, by clustering them in functional classes. The application of 
the powerful Bioinformatics Resources for gene/protein classification provided by DAVID 
knowledgebase, introduced new terms for further remodulation of protein clusters on the basis 
of the multiple functions for individual proteins. 
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Figure . Representative proteomic map of the protein extracted from B-CPAP cells. 2-DE separation was 
performed on IPG gel strips (18 cm, 3.5–10 NL) followed by the SDS-PAGE on a vertical linear-gradient slab 
gel (9–16%T). Protein spots of known identity are labelled with the abbreviated name of the Swiss-Prot 
database. The different isoforms of the same protein are jointly labelled. Other abbreviations: sf = short form; fr 
= fragment. 
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Figure . Representative proteomic map of the protein extracted from 8505C cells. 2-DE separation was 
performed on IPG gel strips (18 cm, 3.5–10 NL) followed by the SDS-PAGE on a vertical linear-gradient slab 
gel (9–16%T). Protein spots of known identity are labelled with the abbreviated name of the Swiss-Prot 
database. The different isoforms of the same protein are jointly labelled. Other abbreviations: sf = short form; fr 
= fragment. 
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The identified proteins were clusterized into ten groups which are the followings: 1) 
Cytoskeleton and associated proteins; 2), Metabolic enzymes; 3) Molecular Chaperones/Heat 
Shock Proteins; 4), Membrane-associated proteins with multiple activities, 5) Calcium 
binding proteins with EF domain, 6) Proteins with binding function, 7) Cell growth and 
proliferation regulators, 8) Protein degradation, 9) Detoxification and redox proteins and 10) 
Proteins with multiple activities. 
 
Quantitative profiling of B-CPAP versus 8505C cell lines 
 
To compare the protein expression levels of 8505C versus B-CPAP cells, we carried out 
triplicate experiments to ensure reproducibility of results (Figure), and we applied the 
densitometric algorithm of the Image Master software, normalizing the data to the sum of all 
spot volumes on gels (% Vol).  
 
 
 
Figure . Miniature of triplicate 2D gels from B-CPAP and 8505C cell lines, used for comparative analyses. 
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The quantitative analysis was performed on 229 identified protein spots (Figure). The average 
of three spot values from three different gels for each cell line was utilized, and expression 
levels of cellular extracts were considered significantly different for ≥ 30% variations. 
The diagam in figure  shows the density profiles of  B-CPAP (blu curve) and 8505C cells (red 
curve). As it can be observed the two profiles are clearly dissimilar in terms of expression 
levels of individual proteins.   
 
 
 
Figure . Diagram of comparative proteomic profiling of B-CPAP and 8505C cells. 
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In particular  the majority of identified proteins, i.e. 63% of the total, are differentially 
expressed while the remaining 37% are unvaried. Among the differentially expressed 53%  
are increased in 8505C proteome while and 47% are reduced in the same maps (Figure a-b). 
 
 
 
Figure. Diagram A  shows invariated and differential proteins, while diagram B displays increased and 
decreased proteins in 8585C respect B-CPAP cell line, expressed in percent. 
 
Concerning the identity of the differentially expressed proteins, it was observed that  the 
majority of them belong to the group of metabolic enzymes, followed by the other groups, 
that in order of representativity are: Cytoskeleton and associated proteins, Molecular 
Chaperones/Heat Shock Protein, Cell growth and proliferation regulators, Membrane-
associated proteins with multiple activities, Detoxification and redox proteins, Calcium 
binding proteins with EF domain, Proteins with binding function, Protein degradation and 
Proteins with multiple activities .  
 
Metabolic enzymes 
The elevated levels of anaerobic metabolism, even in the presence of oxygen, known as the 
"Warburg effect", is a frequent clinical syndrome in oncologic patients, an observation 
40 
 
recognized by several authors, including our group (13-15-19), as a frequent feature of 
neoplastic cells both in vivo and in vitro. 
In both B-CPAP and 8505C proteomic profiles the category of metabolic enzymes includes 
38 protein spots, expressed at different intensity levels between the two cell types. The cluster 
contains anaerobic glycolysis, Krebs Cycle and six proteins of other metabolic pathways 
(AL1A1, DDAH 1, IPYR, 3HIDH, PNPH and VATF). Figure displays the diagram of protein 
fold variation between B-CPAP and 8505C cell lines belonging to metabolic enzymes cluster 
and expressed in a logarithm scale. Relative intensity of protein spots was calculated 
normalizing the data to the sum of all spot volumes on gels (vol%). Each value is the mean of 
three independent determinations and the expression levels of  cellular extracts were 
considered significantly different for ≥ 30% variations. In this cluster we observed the number 
of proteins belonging to the glycolysis pathway is quite high (26 protein spots) and many of 
them show higher levels of expression in 8505C than B-CPAP cell line. Aerobic glycolysis 
induces acidification of the environment cancer by stimulating the development of a more 
aggressive and invasive phenotype that is characteristic of 8505C cell line. The increased 
proteins  in 8505C cell line are: 2 isoforms of ALDOA, 4 isoforms of ENOA, 1 short form of 
ENOA, 4 isoforms of G3P, 1 short form of G3P, 3 isoforms of PGK 1, 2 isoforms of KPYM, 
3 isoforms of TPIS and 1 isoform of PGAM1 and LDHA.  In contrast other glycolytic 
enzymes decrease, these are: LDHB, 1 fragment of  ENOA and 1 isoform of  TPIS. 
 
 
 
Figure. Diagram shows the distribution of metabolic proteins among B-CPAP and 8505C cell lines and  
breakdown of enzymes in metabolic pathways. 
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Among these enzymes two proteins are representative for the glycolytic process: 
α-enolase (ENOA) This protein may acts as a plasminogen receptor (Redlitz A et al. 1995) 
and thus mediates activation of plasmin and extracellular matrix degradation. In tumor cells α-
enolase is up-regulated and supports anaerobic proliferation. α-enolase is expressed at the cell 
surface, where it promotes cancer invasion, and it is subjected to a specific array of post-
translational modifications, namely acetylation, methylation and phosphorylation. Both α-
enolase overexpression and its post-translational modifications could be of diagnostic and 
prognostic value in cancer;  
 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes an important energy-
yielding step in carbohydrate metabolism, the reversible oxidative phosphorylation of 
glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine 
dinucleotide (NAD). The enzyme exists as a tetramer of identical chains. Glucose metabolism 
has a central role in carcinogenesis; among the enzymes controlling this energy production 
pathway, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is of particular interest. This 
enzyme is actually tightly regulated and is involved in numerous cellular functions, such as 
the regulator of cell death; some studies point toward a proapoptotic function, others describe 
a protective role and suggest its participation in tumor progression. 
 
Finally, other proteins (6 protein spots) of this group are Krebs Cycle enzymes. IDH3A  
increase in 8505C cell line, while ODO2, ECHM, ACON, 1 isoform and 1 fragment of 
ATPB. 
 
Cytoskeleton and associated proteins 
Cytoskeleton represents a dynamic structure, that is capable of organizing cytoplasmic 
organelles and intracellular compartments, defining cell polarity and generating both pushing 
and contractile forces. In cell cycle, this structure plays a pivotal role in chromosomal 
separation and cell division. During morphogenesis, cytoskeleton determines cell shape and 
polarity, and promotes stable cell-cell and cell-matrix adhesions. Finally, during cell 
migration it generates protrusive forces at the front and retraction forces at the rear. These are 
all aspects of cell behavior than often go awry in cancer.  
In the group of cytoskeleton and associated proteins (24 protein spots) the increased levels 
were detected for: ACTG, 2 isoforms of ACTB, 2 isoforms of COF1, 2 isoforms of PROF1, 2  
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isoforms of TBB5, 1 fragment of VIME, 1 isoform of VINC, ARPC5 and TYB4. Decreased 
levels were found for 2 isoforms of ACTB, 1 short form of ACTB, 2 isoforms of CAP G, 
EZRI, K1C9, K2C8, TPM3, TBA1B and LMNB1. Figure displays the diagram of protein fold 
variation between B-CPAP and 8505C cell lines belonging to cytoskeleton and associated 
proteins cluster and expressed in a logarithm scale. 
 
 
 
Figure. Diagram shows the distribution of cytoskeleton and associated proteins among B-CPAP and 8505C cell 
lines. 
 
 
The proteins of this category, implicated in different diseases, are briefly described below. 
Actin, cytoplasmic 1 and 2 (ACTB and ACTG) are highly conserved proteins that are 
involved in various types of cell motility and are ubiquitously expressed in all eukaryotic 
cells. Actin and tubulin form highly versatile, dynamic polymers that are implicated in the 
maintenance of cell polarity, in cell cycle, cell division and cell motility. It is interesting to 
note that isoforms of ACTB in 8505C cells are characterized by opposite expression, probably 
due to a different post-translational regulation of the native protein, which require different 
skills for each isoform; 
 
Tubulin alpha-1B and beta-5 chain (TBAIB and TBB5) are the major constituents of 
microtubules and participate in mitotic spindle formation. Therefore, TBB5 increased 
expression in 8505C cells may be related to the rate of cell proliferation. Furthermore, TBAIB 
mRNA overexpression was observed in anaplastic carcinomas (Takano T. 2011). In contrast 
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we have seen low protein expression of TBAIB in 8505C cells and this levels difference 
between mRNA and protein may be due to a post- trascriptional regulation; 
 
Cofilin (COF1) is extremely important for the formation of membrane protrusions and 
directional spikes, through actin-binding activity, involved in the invasive and metastatic 
phenotype of tumour cells (Wang W et al. 2007). We observe the increase of cofilin in 8505C 
cells and this high expression is correlated with the appearance of cytoplasmic extensions, 
showed in these cell line. 
The protein is responsible also for the signal translocation from cytoplasm to nucleus. 
However it can also function as anti-apoptotic factor by binding to the 1433-G protein;  
 
Profilin (PROF1) is involved in the maintenance of cell morphology, cell motility, promoting 
the metastatic process and in signal transduction induced by growth factors; 
 
Vimentin (VIME) is one of the cytoplasmic intermediate filament proteins which are the 
major component of the cytoskeleton. Elevated vimentin expression level well correlates with 
up-regulated migration and invasion of cancer cells (Gilles C et al. 2003); 
 
Vinculin (VINC) is a focal adhesion protein, involved in the mechanical coupling between the 
actin cytoskeleton and the extracellular matrix. The protein is a key protein regulating the 
transmission of contractile forces. High expression of this protein is observed in 8505C cells 
and it has been shown that amplification and overexpression of vinculin are associated with 
increased tumour cell proliferation and progression in advanced prostate cancer (Ruiz C); 
 
Thymosin β4 (TYB4) is known as a 4.9-kDa mass polypeptide that interacts with G-actin and 
functions as a major actin-sequestering protein in cells . It stimulates tissue remodeling, cell 
differentiation, cell proliferation and cell motility. Furthermore, TYB4 induces angiogenesis 
(49) and is involved in the formation of metastasis (28). Enhanced thymosin β4 expression is 
observed in medullary thyroid carcinoma (26) and renal tumor (27) as compared with their 
normal counterparts; 
 
Actin-related protein 2/3 complex subunit 5 (ARPC5) functions as component of the Arp2/3 
complex which is involved in regulation of actin polymerization and together with an 
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activating nucleation-promoting factor (NPF) mediates the formation of branched actin 
networks. Once activated, theArp2/3 complex nucleates new actin filaments and also 
crosslinks actin filaments from end to side-branch, thus creating new barbed ends, which 
drive the extension of the cell‟s leading edge (Mullins et al, 1998).Increased expression of 
Arp2/3 complex in 8505C cells may be related to the creation of cytoplasmic extensions; 
 
Keratin, type I cytoskeletal 9 and type II cytoskeletal 8 (K1C9 and K2C8) are intermediary 
filaments involved in cell motility and cancer progression. In a variety of organs, the 
expression of distinct intermediary filaments are associated with patient prognosis. Moreover, 
K1C9 and K2C8 are considered epithelial markers and decreased of these proteins in 8505C 
cell line may be indicative of  the process of epithelial-mesenchymal transition (EMT) 
correlated with invasive and aggressive phenotype; 
 
Ezrin (EZRI) is involved in connections of major cytoskeletal structures to the plasma 
membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles 
on the apical pole. 
The protein is also implicated in the redistribution of intercellular adhesion molecules and the 
organization of cell membrane structures. The up-regulation expressions of ezrin and moesin 
and the down-regulation expression of E-Cadherin were associated with the invasion and 
metastasis of PTC. Combined detection of Ezrin, Moesin and E-Cadherin in PTC might 
served as an important predictor for the invasion, metastasis and prognosis of PTC (Tao XF 
2009); 
 
Tropomyosin alpha 3 chain (TPM3) is a member of the tropomyosin family of actin-binding 
proteins involved in the contractile system of striated and smooth muscles and the 
cytoskeleton of non-muscle cells. TPM3 provides stability to the filaments and regulates 
access of other actin-binding proteins. Increased expression of this protein in B-CPAP cell 
line may be indicative of greater structural stability associated with a benign phenotype. 
Moreover, rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in 
papillary thyroid carcinomas. TRK oncoproteins display constitutive tyrosine-kinase activity, 
leading to in vitro and in vivo transformation (Greco A. 2010); 
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Lamin-B1 (LMNB1) is involved in most nuclear activities including DNA replication, RNA 
transcription, nuclear and chromatin organization, cell cycle regulation, cell development and 
differentiation, nuclear migration, and apoptosis (Gruenbaum et al., 2003).  
It was found reduced nuclear lamin expression to be an early and frequent ﬁnding in 
gastrointestinal cancer, often accompanied by aberrant cytoplasmic immunolabelling. 
Although the cause of this phenomenon is currently not known, it is assumed that reduced 
nuclear lamin expression may be useful as a marker of malignancy (S F Moss 1999); 
 
Macrophage-capping protein (CAPG) is a ubiquitous actin-modulating protein involved in 
cell signalling, receptor-mediated membrane ruffling, phagocytosis, and motility. CapG has 
generated great interest due to its oncogenic function in the control of cell migration or 
invasion in a variety of cancer cells (Hitomi Nomura 2008). 
 
Molecular chaperones/heat shock proteins 
In group of molecular chaperones/heat shock proteins (22 protein spots) we show the 
increased levels of CARL, 1 isoform of HSP7C, 1 isoform of TERA, HSP74, HSP71, TCTP 
and HSP47. Decreased levels were found for 5 isoforms of HSP60, 1 isoform of HSP7C, 
GRP75, GRP78, CH10, 2 fragments of HYOU1, PDIA1, 2 isoforms of PDIA3 and PPIB. 
Figure displays the diagram of protein fold variation between B-CPAP and 8505C cell lines 
belonging to molecular chaperones/heat shock proteins cluster and expressed in a logarithm 
scale. 
 
 
 
Figure. Diagram shows the distribution of molecular chaperones/heat shock proteins among B-CPAP and 8505C 
cell lines. 
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The proteins of this category, implicated in different diseases, are briefly described below. 
Calreticulin (CARL) is an intracellular calcium-binding chaperone, that when localizes in the 
endoplasmic reticulum (ER) plays important functions in directing proper conformation of 
proteins and glycoproteins, as well as in homeostatic control of cytosolic and ER calcium 
levels. Moreover, it acts as a critical regulator of extracellular functions, particularly by 
mediating cellular migration and phagocytosis of apoptotic cells. The association of 
calreticulin with pathological conditions, such as autoimmune disorders and certain types of 
cancer have been reported. Lwin ZM et al. showed that calreticulin expression is associated 
with more advanced tumors and is a potential prognostic biomarker (Lwin ZM et al. 2010). 
Therefore, the increased levels of CARL may be correlated with aggressive phenotype 
showed in 8505C cells; 
 
Transitional endoplasmic reticulum ATPase (TERA) is necessary for the fragmentation of 
Golgi stacks during mitosis and for their reassembly after mitosis. Involved in the formation 
of the transitional endoplasmic reticulum (tER); 
 
Heat shock proteins (HSPs) are implicated in tumor cell proliferation, differentiation, 
invasion, metastasis, cell death and recognition by the immune system. HSP60 is implicated 
in mitochondrial protein import and macromolecular assembly. It may facilitate the correct 
folding/refolding and assembly of neosynthetized proteins, and also of unfolded/misfolded 
polypeptides generated under stress conditions in the mitochondrial matrix. This protein also 
influences apoptosis; thus HSP60 changes in expression level have been shown to be useful 
new biomarkers for diagnostic and prognostic purposes (Cappello F. 2006). There is some 
inconsistency in that some research shows a positive expression while other shows a negative 
expression, and it seems to depend on the type of cancer. There are different hypotheses to 
explain the effects of positive versus negative expression. Loss of HSP60 expression indicates 
a poor prognosis and the risk of developing tumor infiltration specifically with bladder 
carcinomas (Lebret T. 2003). Moreover, ovarian tumors research has shown that over 
expression is correlated with a better prognosis while a decreased expression is correlated 
with an aggressive tumor (Lebret T. 2003). Finally, it is possible that levels decreased of  
HSP60 in 8505C cells than to B-CPAP cells may be a feature associated to thyroid tumor 
histotype and more aggressive tumor; 
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Translationally-controlled tumor protein (TCTP), a protein involved in calcium binding and 
microtubule stabilization; another study indicate that the interaction between TCTP and p53 
prevents apoptosis by destabilizing p53. Thus, TCTP acts as a negative regulator of apoptosis 
in lung cancer (Rho SB et al. 2011) and it is assumed that this protein may be involved in 
ATC; 
 
Hypoxia up-regulated protein 1 (HYOU1) has a pivotal role in cytoprotective cellular 
mechanisms triggered by oxygen deprivation. May play a role as a molecular chaperone and 
participate in protein folding (Ref.5). Highly expressed in tissues that contain well-developed 
endoplasmic reticulum and synthesize large amounts of secretory proteins. Decreased levels 
of HYOU1 in 8505C cells may be correlated to loss of normal secretory function showed in 
ATC; 
 
Protein disulfide-isomerase (PDIA1 and PDIA3) are involved in the quality control of the 
glycoprotein folding, also by interacting with calreticulin and calnexin; 
PDIA1, also namely cellular thyroid hormone-binding protein, may be involved with other 
chaperones in the structural modification of the tireoglobulin precursor in hormone biogenesis 
(20). 8505C cells express lower levels of protein PDIA1 than B-CPAP cells, and this result 
suggest a lower capability of 8505C cells in maintenance of cell function respect B-CPAP 
cells. 
PDIA3 was found significantly overexpressed in both invasive and borderline ovarian cancers 
(Chay D et al. 2010): 
 
Peptidyl-prolyl cis-trans isomerase B (PPIB) is thought to be essential for protein folding in 
the cells and functional studies also confirmed the role of PPIB in migration and invasion of 
cancer cells. Moreover, modulated TCPZ (T-complex protein 1 subunit zeta) and PPIB are 
two novel indicators for evaluating lymph node metastasis in colorectal cancer (Fei Yue 
2009). 
 
Cell growth and proliferation regulators 
In group of cell growth and proliferation regulators (16 protein spots) the increased levels 
were detected for: 1 isoform of MIF, 2 isoform of CATD, RM12, HNRPM, SPB5, CCNH, 
GDIR and NTF2. Decreased levels were found for: 1 isoform of CATD, 1 isoform of ROA1, 
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ROA2, RUVB1,  PA2G4, PHB and AGR2. Figure displays the diagram of protein fold 
variation between B-CPAP and 8505C cell lines belonging cell growth and proliferation 
regulators cluster and expressed in a logarithm scale.  
 
 
 
Figure. Diagram shows the distribution of cell growth and proliferation regulators among B-CPAP and 8505C 
cell lines. 
 
 
The proteins of this category, implicated in different diseases, are briefly described below. 
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine involved in the 
innate immune response to bacterial pathogens. The expression of MIF at sites of 
inflammation suggests a role as mediator in regulating the function of macrophages in host 
defence. MIF is also thought to favour cancer growth or to render microenvironment 
favourable to cancer progression; 
 
Cathepsin-D (CATD), an aspartyl lysosomal protease expressed in all tissues, may plays a 
role in antigen processing, cell proliferation, tissue renewal and activation of different pro 
hormones. CATD expression level is used also as a biological marker for prognosis of breast 
cancer (25). Interestingly, its high expression (two isoforms) in 8505C cells could be to 
indicate a possible involvement also in thyroid cancer; 
 
39S ribosomal protein L12 (RM12) is involved in protein synthesis and the expression levels 
of RM12 were found altered in prostate cancer (Lexander et al., 2005); 
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Heterogeneous nuclear ribonucleoprotein M (HNRPM) belongs to family of heterogeneous 
nuclear ribonucleoproteins (hnRNP) and  research has shown that these proteins have central 
roles in DNA repair, telomere biogenesis, cell signaling and in regulating gene expression at 
both transcriptional and translational levels. Through these key cellular functions, individual 
hnRNPs have a variety of potential roles in tumour development and progression including 
the inhibition of apoptosis, angiogenesis and cell invasion (Carpenter B 2005). 
 
Serpin B5 (SPB5) was originally described as a breast tumour suppressor, a gene which was 
active in normal breast epithelial cells and which was down-regulated progressively towards 
malignancy. Several works suggest that SPB5 reduces angiogenesis,  tumour invasiveness, 
growth and metastasis. Moreover, it seems that SPB5 expression in thyroid carcinomas is 
closely associated with a lack of differentiation of the tumour cells (Ogasawara S. 2004). 
Decreased expression level of this protein in 8505C cell line therefore may be correlated with 
a dedifferentiation from PTC to ATC; 
 
Cyclin-H (CCNH) plays a key role in cell cycle regulation by modulating the activity of 
cyclin dependent kinase 7 (CDK7) which phosphorylates CDK1, 2, 4 and 6. In addition, it has 
been demostrated that CCNH expression is increased in gastrointestinal stromal tumours with 
very-high risk of malignancy. High expression level of this protein in 8505C cells thus may 
be associated to  malignancy and poor prognosis; 
 
Rho GDP-dissociation inhibitor 1 (GDIR) regulates the GDP/GTP exchange reaction of the 
Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of 
GTP to them. This protein plays an essential role in many cellular functions through its 
interactions with Rho family GTPases. RhoGDI is frequently overexpressed in human tumors 
and chemoresistant cancer cell lines, raising the possibility that RhoGDI might play a role in 
the development of drug resistance in cancer cells (Zhang B et al. 2005); 
 
Nuclear transport factor 2 (NTF2) is implicated in nuclear import RanGDP. Ran protein 
belongs to RAS family and it is involved in RNA and protein trafficking within the nucleus 
and in mitotic spindle formation (Stewart et al., 2000); 
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Heterogeneous nuclear ribonucleoproteins A1 and A2/B1 (ROA1 and ROA2) are RNA 
binding proteins involved in a variety of functions, including regulation of transcription, 
mRNA metabolism and translation. Alterated expression of heterogeneous nuclear 
ribonucleoproteins has been reported in several types of cancers. ROA1 is overexpressed in 
oligodendrogliomas (Xu X. 2001) and chronic myelogenous leukemia (Iervolino A 2002). 
ROA1 expression is also increased in myeloid progenitor cells expressing the BRC/ABL 
oncoprotein. In these cells, an alteration of ROA1 normal functioning results in a decrease of 
colony formation and tumorigenesis of these transformed cells, in part due to a 
downregulation of the antiapoptotic factor Bcl-xL (Iervolino A 2002). ROA2 is overexpressed 
in lung, breast, pancreatic and esophageal cancer (Zhou J. 2001 and Fielding P 1999). In 
contrast, loss of ROA2 expression was observed in thyroid neoplasms and this event seems to 
be a characteristic feature of thyroid malignant lesions (Bidot P. 2001). Indeed, we observed 
ROA2 expression decrease in 8505C respect B-CPAP cells and thus the detection of this 
protein may be useful to distinguish different thyroid tumor histotypes; 
 
RuvB-like 1 (RUVB1) is a component of the NuA4 histone acetyltransferase complex which 
is involved in transcriptional activation of select genes principally by acetylation of 
nucleosomal histones H4 and H2A. This modification promotes interaction of the modified 
histones with other proteins which positively regulate transcription. This complex may be 
required for the activation of transcriptional programs associated with oncogene and proto-
oncogene mediated growth induction, tumor suppressor mediated growth arrest and 
replicative senescence, apoptosis, and DNA repair; 
 
Proliferation-associated protein 2G4 (PA2G4) is involved in ribosome assembly and rRNA 
processing regulation. PA2G4 can interact also with the cytoplasmic domain of ErbB3 
receptor and may contribute to growth through the signals transduction. Indeed, this protein 
has been implicated in growth inhibition and the induction of differentiation of breast cancer 
cells (Xia X. 2001); 
 
Prohibitin (PHB) has a role in regulating cell proliferation; it may be also localized in the 
mitochondria where it might have a role in the maintenance of mitochondrial function and 
protection against senescence. PHB has potential roles of tumor suppressor, through an anti-
proliferative function or as a regulator of cell-cycle progression and apoptosis. 
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Anterior gradient protein 2 homolog (AGR2) is a secretory protein that may play a role in cell 
migration, cell differentiation and cell growth. This protein is highly expressed in 
adenocarcinomas of the esophagus, pancreas, breast, and prostate (Zheng Wang. 2008). In 
particular, AGR2 may be used as a means of detecting the outcome of hormonal therapy in 
patients with breast cancer. Although currently there aren't AGR2 experimental evidences for 
thyroid cancer, the increased expression level was detected in B-CPAP cell line and thus 
AGR2 may represent a marker associated with PTC. 
 
Membrane-associated proteins with multiple activities 
In the category of membrane-associated proteins with multiple activities (11 protein spots) 
high levels were showed for 1 isoform of ANXA1, 2 isoforms of ANXA2, 2 isoforms of 
VDAC1, LEG1 and 1 isoform of LEG3, while low levels for 1 short form of  ANXA1, 1 short 
form of ANXA2, 1 isoform of LEG3 and ANXA4. Figure displays the diagram of protein 
fold variation between B-CPAP and 8505C cell lines belonging to molecular membrane-
associated proteins cluster and expressed in a logarithm scale. 
 
 
 
Figure. Diagram shows the distribution of membrane-associated proteins with multiple activities among B-
CPAP and 8505C cell lines. 
 
 
The proteins of this category, implicated in different diseases, are briefly described below. 
Annexins (ANXA1, ANXA2 and ANXA4) are a group of structurally related calcium-binding 
proteins that have a domain that binds to phospholipids and an amino terminal domain that 
determines specificity (10-12). The annexins are involved in regulation of membrane 
trafficking, cellular adhesion, and possible tumorigenesis. 
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ANXA1 promotes metastasis formation by enhancing TGFbeta/Smad signalling and actin 
reorganization, which facilitates an EMT-like switch, thereby allowing efficient cell migration 
and invasion of metastatic breast cancer cells (de Graauw M et al. 2010). It has been reported 
that ANXA1 is up-regulated in human breast cancer [17], hepatocellular carcinoma [18], and 
pituitary adenoma [19] and down-regulated in human esophageal squamous cell carcinoma 
[20], prostate cancer [21], and endometrial carcinoma [22]. A number of studies have also 
shown that can ANXA1 promote cell death but also increase resistance to apoptosis. The 
underlying causes for these differences are not known and may be dependent on cell type or 
due to differences in the differentiation status of individual cell types.   
ANXA2 is involved in cell proliferation and membrane physiology (Gerke et al, 2005). It was 
also observed that ANXA2 expression in renal cell carcinomas was associated with metastasis 
and poor prognosis. The ANXA2 might play an important role in the development of 
metastasis and might be a useful marker for formulating individualised follow-up protocols as 
well as for identifying patients suitable for adjuvant therapy (Y Ohno 2009). 
ANXA4 plays a role in paclitaxel resistance in lung and colon cancer cell lines and it is 
among one of the earliest proteins that is induced in cells in response to cytotoxic stress such 
as antimitotic drug treatment (E Kyu-Ho Han 2000). 
 
Voltage-dependent anion-selective channel protein 1 (VDAC1) is a component of the 
mitochondrial permeability transition pore, regulates mitochondrial ATP/ADP exchange 
suggesting that its over-expression could be associated with energy dependent processes 
including increased proliferation and invasiveness (Abu-Hamad S. 2006). Gene expression 
analysis has identified VDAC1 gene expression as a predictor of poor outcome in NSCLC 
(non-small cell lung cancer) (Claire Grills 2011). Therefore, levels increased of VDAC1 in 
8585C cell line may be associated with aggressive tumour behaviour. 
 
Galectin 1 and 3 (LEG1 and LEG3) are lectin-binding proteins expressed ubiquitously in 
mammalian organism. Since its discovery, the galectins were shown to participate in many 
cellular processes. The most extensively studied galectins are LEG1 and LEG3, which have 
molecular weights of 14.5 kD and 29 to 35 kD, respectively. 
Several works indicate that LEG1 induces apoptosis of activated human T cells and this 
process represents a new mechanism regulating the immune response (21). Moreover, the 
participation in angiogenesis suggest that protein could be involved in tumor progression.  
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Recently, LEG1 expression was reported to be low in normal rat thyroid cell lines and very 
high in oncogene-transformed cell lines (25). Thus, cellular transformation in cultured thyroid 
cells was accompanied by a loss of differentiated functions and by a dramatic increase in 
LEG1 mRNA expression. Furthermore, the level of LEG1 mRNA was higher in human 
thyroid cancer than in normal thyroid tissue (25). These results suggest that LEG1 could serve 
as marker for differentiating between benign and malignant thyroid neoplasms. Because a 
greater differential expression of LEG1 was observed  between B-CPAP and 8505C cell line, 
this protein can also be used  as marker associated to cancer thyroid histotype and malignancy 
grade.  
LEG3 expression has also been linked to cell proliferation, because it was enhanced within a 
short time after mitogenic stimulation of quiescent mouse fibroblasts (45). Increased 
expression of LEG3 was also seen in thyroid malignancies. 
 
Detoxification and redox proteins 
Detoxification and redox proteins are related enzymes performing important roles in the cell 
catabolism and protection against metabolic stresses. In this group (11 protein spot) high 
levels were observed for 1 isoform of GSTO1, 1 isoform of THIO, 1 isoform of SODM, 
PRDX6 and CAH1, whereas low levels for 1 isoform of GSTO1, 1 isoform of PRDX2, 1 
short form of SODC, 1 isoform of SODM, 1 isoform of AK1BA and AK1C3. Figure displays 
the diagram of protein fold variation between B-CPAP and 8505C cell lines belonging to 
detoxification and redox proteins cluster and expressed in a logarithm scale. 
 
 
 
Figure. Diagram shows the distribution of detoxification redox proteins cluster among B-CPAP and 8505C cell 
lines. 
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The proteins of this category, implicated in different diseases, are briefly described below. 
Glutathione transferase omega-1 (GSTO1) plays an important role in detoxification by 
catalysing the conjugation of many hydrophobic and electrophilic compounds with reduced 
glutathione. Aberrant expression of GSTO1 is associated with carcinogenesis and 
development of multidrug resistance. Moreover, it is interesting to note that isoforms of 
GSTO1 in 8505C cells are characterized by opposite expression, probably due to a different 
post-translational regulation of the native protein, which require different skills for each 
isoform; 
Thioredoxin (THIO) is a small redox-regulating protein, which plays crucial roles in 
maintaining cellular redox homeostasis and cell survival and is highly expressed in many 
cancers.  
Several studies implicate over-expression of THIO as one of the enhancers of cancer cell 
growth, either through the direct stimulation of cancer cell growth or through the inhibition of 
cancer cell apoptosis. Moreover, high levels of THIO expression have also been correlated 
with highly invasive and metastatic tumor activity both in vitro and in vivo (Ceccarelli 2008 
and Lincoln 2003). An in vitro study using a neuroblastoma cell line revealed a possible 
mechanism by which THIO can enhance the metastasis of cancer cells. THIO was shown to 
stimulate cell invasion in these cells and to promote overall matrix metalloproteinase (MMP) 
activity by preferentially inhibiting the MMP inhibitors (Farina 2001). Therefore, it is 
possible that this mechanism is triggered in the ATC since an increased expression of THIO 
and MMPs was detected in 8505C cells. 
 
Superoxide dismutase [Cu-Zn] and [Mn] mitochondrial (SODC and SODM) destroy radicals 
which are normally produced within the cells and which are toxic to biological systems.  
 
Peroxiredoxin 2 and 6 (PRDX2 and PRDX6) are family of antioxidant enzymes, which 
reduce hydrogen peroxide and alkyl hydroperoxides. The encoded proteins may play an 
antioxidant protective role in cells, and may contribute to the antiviral activity of CD8(+) T-
cells. PRDX2 may have a proliferative effect and play a role in cancer development or 
progression, while PRDX6 may be involved in the regulation of phospholipid turnover. 
 
Carbonic anhydrase 1 (CAH1) is a member of a family of isoenzymes that catalyse the 
reversible hydration of carbon dioxide and participate in various biological processes like 
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electrolyte transport and maintenance of pH. Moreover, CAH1 is highly expressed in 
intestinal mucosa and takes care of the maintenance of the intracolonic and cellular pH. In 
colorectal tumours CAH1 is significantly less expressed than in normal mucosa (Kivela A. J. 
2001). 
 
Aldo-keto reductase family 1 member A1 and C3 (AK1BA and AK1C3) belong to aldo/keto 
reductase family and are involved in the reduction of biogenic and xenobiotic aldehydes. 
 
Calcium binding proteins 
One other group of interest is the calcium binding proteins (8 protein spots), including some 
protein forms of the S100 protein family and calmodulin. Increased levels were detected for: 1 
isoform of S100-A6 and 1 isoform of S100-A7, while decreased levels were found for: 
CALM, SEGN, 1 isoform of S100-A7, 2 isoforms of  S100-P and S100-A13. Figure displays 
the diagram of protein fold variation between B-CPAP and 8505C cell lines belonging to 
calcium binding proteins cluster and expressed in a logarithm scale. 
 
 
 
Figure. Diagram shows the distribution of calcium binding proteins cluster among B-CPAP and 8505C cell 
lines. 
 
 
The proteins of this category, implicated in different diseases, are briefly described below. 
Proteins S100 (S100) are small, acidic- Ca2 binding proteins, found exclusively in vertebrates 
and are involved in several biological processes, such as cell cycle regulation, cell growth, 
cell differentiation and motility through a broad range of intracellular and extracellular 
activities (22-23). Moreover, dramatic changes in S100 proteins expression are exhibit in of 
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different forms of cancer. The S100-RAGE signalling pathway plays an important role in 
linking inflammation and cancer and in tumour cell survival and malignant progression 
(RAGE-deficient tumours are characterized by accelerated apoptosis, reduced activation of 
NFκB and significantly impaired proliferation). 
In particular, our attention has focused on: 
S100A6 was detected in melanoma, pancreatic and colorectal cancers and the expression of 
this protein may be to correlate with tumor growth and metastatic progression suggesting a 
potential role for S100A6 in the development of malignancy (Lesniak et al., 2009; Salama et 
al., 2008); 
 
S100A7 is up-regulated in ductal carcinoma in situ and ER negative invasive breast cancer 
and expression correlates with aggressive phenotype and patient survival (Emberley et al., 
2004); 
 
S100P is often in association with tumor progression, and may be considerated a potential 
tumor biomarker and therapeutic target. However, the S100P role in tumor progression is not 
completely understood; 
 
S100A13 is widely expressed in many types of tissues, with particularly high expression in 
the thyroid gland. Therefore, decreased expression of S100A13 in 8505C cell line may 
indicate low differentiated level typical of ATC. 
 
Calmodulin (CALM) mediates the control of a large number of enzymes, ion channels and 
other proteins by Ca2+. Recent evidence suggests that calmodulin may regulate cellular 
proliferation and that its function may be altered in malignancy. The discovery of drugs wich 
antagonize the action of calmodulin led to the study of these antagonists against tumor cells; 
 
Secretagogin (SEGN) is considered a marker for neuroendocrine differentiation expressed at 
high levels in the pancreatic islets of Langerhans. The SEGN function is unknown,but it has 
been suggested that this protein influences the calcium-influx, insulin secretion and 
proliferation. Previous microarray-based studies have demonstrated that this protein is highly 
expressed in normal colon mucosa compared to basal expression in colon adenocarcinomas 
(Birkenkamp-Demtröder K. 2005). 
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Proteins with binding function 
In the category of proteins with binding function (8 protein spots) we observed the increased 
levels of  SH3L1, FABP5 and U3IP2, whereas decrease levels of ACBP, RABP2 and COPE. 
Figure displays the diagram of protein fold variation between B-CPAP and 8505C cell lines 
belonging to proteins with binding function cluster and expressed in a logarithm scale. 
 
 
 
Figure. Diagram shows the distribution of proteins with binding function cluster among B-CPAP and 8505C cell 
lines. 
 
 
The proteins of this category, implicated in different diseases, are briefly described below. 
SH3 domain-binding glutamic acid-rich-like protein (SH3L1) is up-regulated in many cancers 
such as lung and pancreatic and implicated in increased resistance of cancer cells to free-
radicals. There is little current evidence which directly links SH3L1 with survival in cancer 
cells, however the protein has recently been identified as up-regulated in glioblastoma 
multiforme compared to normal cerebral tissue on proteomic analysis (Khalil AA 2007). 
Moreover, this protein is potentially involved in resistance of cells to the apoptosis-inducing 
affect of TNF-α.( Xu C 2005); 
 
Fatty acid-binding protein epidermal (FABP5) belongs to the conserved multigene family of 
the intracellular lipid-binding proteins (iLBPs). Various functions have been proposed for 
these proteins, including the promotion of cellular uptake and transport of fatty acids, the 
targeting of fatty acids to specific metabolic pathways, and the participation in the regulation 
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of gene expression and cell growth (H Haunerland 2004). In particular, FABP5 may be 
involved in mechanisms leading to chemoresistance in pancreatic adenocarcinoma; 
 
U3 small nucleolar RNA-interacting protein 2 (U3IP2) is a component of a nucleolar small 
nuclear ribonucleoprotein particle (snoRNP) and likely this protein plays a role in the 
processing and modification of pre-ribosomal RNA; 
 
Acyl-CoA-binding protein (ACBP) is involved in the regulation of multiple biological 
processes such as neuronal Cl
-
 influx, steroidogenesis, acyl-CoA metabolism, and glucose-
mediated insulin secretion. In addition, the high expression of ACBP in brain tumors might 
play a role in the neoplastic growth of glial cells via the mitochondrial benzodiazepine 
receptor, or it may be involved in the regulation of the high energy consumption of these 
tumors via acyl-CoA metabolism (H AIho 1995); 
 
Cellular retinoic acid-binding protein 2 (RABP2) is an intracellular lipid-binding protein and 
it is involved in the process of retinoic acid transport to the nucleus. A research have 
demonstrated that RABP2 mRNA and protein  are down-regulated in prostate cancer 
(Okuducu AF 2005). 
 
Coatomer subunit epsilon (COPE) is involved in the regulation of intracellular protein 
trafficking between the endoplasmic reticulum and the Golgi complex (24). 8505C cells 
express lower levels of this protein than B-CPAP cells and it may correlate with the tendency 
of B-CPAP cells to maintain cells function in vesicular trafficking typical of thyroid cells. 
 
Protein-degradation 
The protein-degradation machinery is a very important cellular design to maintain protein 
homeostasis and cellular health. In group of protein degradation (7 protein spots) high levels 
were found for UCHL1, PSME1 and PSA6, while low levels for UBIQ, PSA1, PSB4 and 
SUMO1. Figure displays the diagram of protein fold variation between B-CPAP and 8505C 
cell lines belonging protein-degradationcluster and expressed in a logarithm scale.  
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Figure. Diagram shows the distribution of protein degradation cluster among B-CPAP and 8505C cell lines. 
 
 
The proteins of this category, implicated in different diseases, are briefly described below. 
Ubiquitin Carboxyl-Terminal Hydrolase-L1 (UCHL1) is a deubiquitinating enzyme that is 
highly expressed throughout the central and peripheral nervous system and in cells of the 
diffuse neuroendocrine system. This protein exhibits a variable expression pattern in cancer, 
acting either as a tumour suppressor or promoter, depending on the type of cancer. In non-
small cell lung carcinoma (NSCLC), UCH-L1 is highly expressed and is associated with an 
advanced tumour stage. This suggests UCH-L1 may be involved in oncogenic transformation 
and tumour invasion in NSCLC (Katy S Orr 2011). Therefore, high expression level of this 
protein in 8505C cells may be associated to an advanced stage of thyroid cancer. 
 
Ubiquitin–proteasome system is involved in the regulation of various cellular processes; 
among them is the important role of targeting proteins for degradation. Nevertheless, 
ubiquitination also plays a significant role in DNA damage repair, cellular signaling, 
intracellular trafficking, and ribosomal biogenesis (Li and Ye, 2008). Moreover, ubiquitin–
proteasome system alterations are been associated to the initiation and progression of cancer 
and this knowledge is beginning to be exploited for molecular diagnostics and the 
development of new strategies to fight cancer (Nature 2008). in particular, it has been 
demonstrated that Inhibition of the proteasome is effective in reducing cell growth and induce 
apoptosis of ATC in vitro and inhibit tumor growth and vascularization in vivo (Constantine 
S. 2006) 
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Proteins with multiple activities  
Finally, in the category of proteins with multiple activities (2 protein spots) high levels were 
showed in SAHH, while low level in PNPO. Figure displays the diagram of protein fold 
variation between B-CPAP and 8505C cell lines belonging proteins with multiple activities 
cluster and expressed in a logarithm scale.  
 
 
 
Figure. Diagram shows the distribution of proteins with multiple activities cluster among B-CPAP and 8505C 
cell lines. 
 
 
In particular, our attention has been focused on highly expressed proteins (cut - off <2) in B-
CPAP and 8505C cells. This screening has highlighted 32 proteins and most of these belong 
to the group of metabolic enzymes, cytoskeleton and associated proteins and molecular 
chaperones / heat shock proteins. These results highlight the crucial role of glycolysis, cell 
motility and protein folding in thyroid tumorigenesis . Moreover, the differential expression 
of these proteins in B-CPAP and 8505C cells could provide the opportunity to identify 
potential markers associated with PTC and ATC . 
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Cell motility (Scratch Assay) 
Cell motility is a complex phenomenon primarily driven by the actin network and it is 
essential to a variety of biological processes such as morphogenesis, wound healing, immune 
response and cancer metastasis.  
We studied the cell motility of  B-CPAP and 8505C cell lines using scratch assay to assess the 
differences in the migratory and invasive abilities associated with aggressive phenotype. We 
found that wound healing was observable between 6 and 24 hrs after wounding with a pipette 
(Fig.). Significant cell migration was seen at 6 hrs (Fig. A-B) with formation of lamella, 
protrusions and intercellular contacts at the wound margin in 8505C cells. After 24 hrs (Fig. 
C-D) wound was completely healed in 8505C unlike the B-CPAP, where it wasn‟t observed 
the wound healing. Cell motility results showed that the 8505C cells display a very aggressive 
in vitro phenotype respect to B-CPAP. 
 
 
 
Figure. Representative optical micrographs of B-CPAP and 8505C cell lines  at different time from scratch: 6h 
(A B-CPAP and B 8505C) and 24h (C B-CPAP and D 8505C); 
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Zymographic analysis and Western Blot validation 
A deregulated proteolysis of ECM molecules in thyroid tumors may cause the alteration of 
follicular structure and the loss of cell polarity. These events, in turn, may induce neoplastic 
cells to elude cell–cell and cell–ECM adhesions, promoting cancer progression (27). In 
general, these alterations are correlated with poor prognosis in many tumor histotypes, where 
a positive relationship between the increase of MMPs and the malignancy grade has also been 
observed (28). Moreover, “in vitro” studies performed on thyroid cells suggest that BRAF 
V600E mutation promotes the invasion, by increasing the expression of certain 
metalloproteinases (MMP-3, MMP-9, MMP-13) (29-27). For these reasons we focused on 
MMP-2 and MMP-9 activity which are over-produced in several carcinomas. B-CPAP cell 
line express the MMP-2 and MMP9, with activity levels quite low compared with 8505C cell 
line characterized by high gelatinolytic activity. 
Figure shows the results of a representative zymogram of B-CPAP and 8505C conditioned 
media (Fig. A) loaded at the same protein concentration (10 µg/lane). B-CPAP sample 
contained only two gelatinolytic bands corresponding to monomeric pro-MMP-9 (92 kDa) 
and pro-MMP-2 (72 kDa). Unlike, 8505C sample showed increased activity of proenzymatic 
forms (pro-MMP-9 and pro-MMP-2), but also displayed a band corresponding to MMP-9 (86 
kDa). In order to validate our results, we performed immunoblot analyses on B-CPAP and 
8505C conditioned media (20 µg), using a specific antibody to MMP-9 and MMP-2, as 
described in materials and methods. The antibodies have given a positive response for 8505C 
conditioned medium (Fig. B). 
 
 
Figure .A) Gelatin zymogram (7.5% SDS-PAGE) of conditioned media from B-CPAP and 8505C cell lines and 
B) Western blot of conditioned media probed with anti-MMP 9 and  anti-MMP 2 antibodies. 
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In particular, the antibody MMP9 recognized two bands at high molecular weight (180 kDa) 
corresponding to dimeric MMP-9 and pro-MMP9. The reaction to anti-MMP-2 localized in 
the 70 kDa region may correspond to pro-MMP-2. In contrast, in conditioned media of B-
CPAP, the antibodies have given a negative reaction, reflecting the low levels of enzymatic 
expression in this cell line.  
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